Updated Guidelines Shift Genetic Evaluation for Global Developmental Delay and Intellectual Disability

Earlier use of genomic testing leads to faster, more accurate diagnoses

Recent updates to national guidelines now support earlier genetic testing in children with global developmental delay (GDD) and intellectual disability (ID). The American Academy of Pediatrics (AAP) and the American College of Medical Genetics and Genomics (ACMG) now recommend exome or genome sequencing as a first-tier test for most patients with unexplained GDD or ID, citing higher diagnostic yield and greater cost-effectiveness when testing is performed earlier in the diagnostic process.

These updates reflect rapid advances in genomic medicine and a growing body of evidence demonstrating that earlier identification of an underlying genetic diagnosis can shorten the diagnostic journey for families and influence clinical care.

Why Genetics Matter

GDD and ID are among the most common indications for genetic evaluation. Genetic etiologies including chromosomal, monogenic and complex genetic conditions account for up to 50% of identified causes. 

While prenatal, perinatal and postnatal factors may also contribute, genetics plays a central role in many cases particularly when delays are unexplained or accompanied by additional clinical features like congenital malformations or dysmorphic features.

Historically, evaluation followed a tiered approach that often began with chromosomal microarray, Fragile X testing and metabolic screening. In retrospect, this sequential testing strategy resulted in prolonged diagnostic timelines and increased testing burden for families.

Advances in next-generation sequencing have reshaped this approach. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) allow simultaneous analysis of thousands of genes known to be associated with neurodevelopmental disorders and can detect deletions and duplications with equal or improved sensitivity to chromosomal microarrays. The comprehensive genomic approach improves the likelihood of identifying an underlying diagnosis earlier, which can guide condition management, inform prognosis and support family counseling.

Evidence Supporting First-Tier Genomic Sequencing

Across multiple studies, diagnostic yield for exome or genome sequencing ranges from 28-43%, compared with approximately 15-20% for chromosomal microarray alone. When used as first-line testing, exome or genome sequencing leads to more diagnoses, lower overall health care costs and shorter time to diagnosis. Families also place strong value on negative results, underscoring that diagnostic yield alone does not fully capture the clinical utility of genomic sequence testing.

Several factors influence diagnostic yield, including the severity of ID, presence of congenital anomalies or dysmorphic features and neurologic comorbidities. Testing strategy also matters. Trio-based sequencing, which includes parental samples, provides an additional 10-15% diagnostic yield by facilitating identification of de novo variants and clarifying variant inheritance.

Updated Role of Other Testing Modalities

While genomic sequencing has moved earlier in the diagnostic process, other testing modalities remain important. Chromosomal microarray continues to be recommended as a first-tier study and may be performed sequentially or concurrently with exome sequencing, depending on clinical presentation and testing availability.

Fragile X testing is no longer recommended as a first-line test due to its low diagnostic yield and should be reserved for patients with suggestive clinical features or family history, or as a follow-up test after non-diagnostic first-tier studies. Similarly, metabolic testing for inborn errors of metabolism has shifted from first-tier to second-tier evaluation and is typically considered after non-diagnostic genomic sequencing.

Comprehensive Genetic Care at Children’s Wisconsin

At Children’s Wisconsin, updated guidelines are reviewed and implemented by the Genetics and Genomics Program. The multidisciplinary team includes genetic advanced practice providers, genetic counselors and metabolic dietitians who collaborate closely with geneticists and other specialists to deliver individualized care. Nationally recognized as a Center of Excellence by the National Organization for Rare Diseases and an Undiagnosed Disease Network site, the program offers expertise across neurodevelopmental disorders, multiple congenital malformations, hereditary connective tissue disorders, inborn errors of metabolism, neurogenetics, rare disease and complex genetic conditions. The program uses an innovative hub-and-spoke model integrating genetic counselors into specialty clinics across the Milwaukee Campus, improving access to genetic expertise and streamlining care for patients and referring providers.

Implications for Referring Providers

These updated guidelines emphasize the importance of early referral to genetics and timely consideration of exome or genome sequencing for children with unexplained GDD or ID. Earlier diagnosis can directly inform medical management, guide anticipatory surveillance, identify treatment opportunities, improve coordination of care and support family counseling.

For referring providers, incorporating genomic testing earlier in evaluation can reduce unnecessary testing and delays in care, providing families with clearer answers during a critical period of development and prior to the onset of many or all symptoms of the diagnosis.